Baruch Kuppermann, MD
Retina Specialist · Irvine, CANPI 1326128455
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $908,286 of the $1,048,682 with a category attached, or 86.6%. Ocular Therapeutix, Inc. accounts for 62.2% of it on its own, with 23 other manufacturers making up the rest. 2025 is the largest year on record at $426,211, 2.8 times the $150,885 reported in 2019. Among retina specialist clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 312 payments — averaging $3361.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ocular Therapeutix, Inc.$652K
- AbbVie$261K
- Genentech USA, Inc.$42K
- Apellis Pharmaceuticals, Inc.$16K
- Coherus Oncology, Inc.$16K
- Regeneron Healthcare Solutions, Inc.$14K
- plus $47K from 18 others
Across 37 payments — averaging $9201.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Apellis Pharmaceuticals, Inc.$118K
- Novartis$111K
- Eyepoint US, Inc.$39K
- Boehringer Ingelheim$38K
- Regeneron$34K
What the payments were for
- Consulting fees$908,28687%
- Speaking & faculty fees$104,31510%
- Travel & lodging$24,1142%
- Food & beverage$11,9051%
- Education$630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ocular Therapeutix, Inc. | 51 | $652,304 |
| AbbVie(2 entities) | 138 | $260,616 |
| Genentech USA, Inc. | 27 | $41,709 |
| Apellis Pharmaceuticals, Inc. | 16 | $16,486 |
| Coherus Oncology, Inc. | 8 | $16,058 |
| Regeneron Healthcare Solutions, Inc. | 18 | $14,089 |
| Amgen | 3 | $9,947 |
| Novartis | 4 | $9,024 |
| Hexal AG | 3 | $7,557 |
| Bausch & Lomb Americas Inc. | 11 | $6,985 |
| Eyepoint US, Inc. | 11 | $6,677 |
| F. Hoffmann-la Roche AG | 2 | $4,353 |
| Biocryst Pharmaceuticals, Inc. | 1 | $1,100 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $403 |
| Nevro Corp. | 2 | $291 |
| Regeneron | 5 | $265 |
| Dutch Ophthalmic, USA | 1 | $173 |
| Carl Zeiss Meditec USA, Inc. | 1 | $163 |
| Astellas Pharma US Inc | 2 | $148 |
| Alimera Sciences, Inc. | 1 | $125 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $90 |
| Astellas Pharma Global Development | 1 | $61 |
| Rxsight Inc | 1 | $40 |
| Glaukos Corporation | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,048,682 in reported general payments places this provider in the 95th percentile of 187 retina specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other retina specialist in Irvine
- Mitul MehtaIrvine$192K
- Andrew BrowneIrvine$82K
- Nadeem VaidyaIrvine$18K
- Kapil MishraIrvine$15K
- Dilsher DhootSanta Barbara$1.9M
- Ehsan RahimyStanford$1.5M
- Darius MoshfeghiPalo Alto$1.4M
- Nathan SteinleSanta Barbara$1.1M
- Roger GoldbergWalnut Creek$1.1M
- Carlos Medina MendezSacramento$548K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.